Nuclear and Mitochondrial Genome, Epigenome and Gut Microbiome: Emerging Molecular Biomarkers for Parkinson's Disease
- PMID: 34576000
- PMCID: PMC8471599
- DOI: 10.3390/ijms22189839
Nuclear and Mitochondrial Genome, Epigenome and Gut Microbiome: Emerging Molecular Biomarkers for Parkinson's Disease
Abstract
Background: Parkinson's disease (PD) is currently the second most common neurodegenerative disorder, burdening about 10 million elderly individuals worldwide. The multifactorial nature of PD poses a difficult obstacle for understanding the mechanisms involved in its onset and progression. Currently, diagnosis depends on the appearance of clinical signs, some of which are shared among various neurologic disorders, hindering early diagnosis. There are no effective tools to prevent PD onset, detect the disease in early stages or accurately report the risk of disease progression. Hence, there is an increasing demand for biomarkers that may identify disease onset and progression, as treatment-based medicine may not be the best approach for PD. Over the last few decades, the search for molecular markers to predict susceptibility, aid in accurate diagnosis and evaluate the progress of PD have intensified, but strategies aimed to improve individualized patient care have not yet been established.
Conclusions: Genomic variation, regulation by epigenomic mechanisms, as well as the influence of the host gut microbiome seem to have a crucial role in the onset and progress of PD, thus are considered potential biomarkers. As such, the human nuclear and mitochondrial genome, epigenome, and the host gut microbiome might be the key elements to the rise of personalized medicine for PD patients.
Keywords: Parkinson’s disease; biomarkers; epigenetics; genetics; microbiome; mitochondria; neurodegeneration; non-coding RNAs; precision medicine.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the writing of the manuscript, or in the decision to publish the results.
Figures
References
-
- Vinasco-Sandoval T., Moreira F.C., Vidal A.F., Pinto P., Ribeiro-dos-Santos A.M., Cruz R.L.S., Cabral G.F., Anaissi A.K.M., Lopes K.d.P., Ribeiro-dos-Santos A. Global analyses of expressed piwi-interacting RNAs in gastric cancer. Int. J. Mol. Sci. 2020;21:7656. doi: 10.3390/ijms21207656. - DOI - PMC - PubMed
-
- Vidal A.F., Ribeiro-dos-Santos A.M., Vinasco-Sandoval T., Magalhães L., Pinto P., Anaissi A.K.M., Demachki S., de Assumpção P.P., dos Santos S.E.B., Ribeiro-dos-Santos A. The comprehensive expression analysis of circular RNAs in gastric cancer and its association with field cancerization. Sci. Rep. 2017;7:14551. doi: 10.1038/s41598-017-15061-w. - DOI - PMC - PubMed
-
- Cook Shukla L., Schulze J., Farlow J., Pankratz N.D., Wojcieszek J., Foroud T. Parkinson Disease Overview. GeneReviews® 2004. [(accessed on 25 July 2019)]. Available online: https://www.ncbi.nlm.nih.gov/books/NBK1223/
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
